Life Sciences Consulting Report (Feb 2025)

The life sciences consulting market is experiencing unprecedented M&A activity, driven by private equity-backed consolidation and the rapid expansion of advanced therapeutics, AI, and digital transformation.

With nearly 80% of transactions led by PE investors, firms are actively scaling through acquisitions to enhance regulatory, clinical, and commercialization capabilities. Deal valuations remain strong, reflecting the premium placed on niche expertise and innovation.

Download the report to gain insights on:

  • M&A momentum – Over 400 deals since 2018, with a record 100 deals in 2024
  • Private equity dominance – PE firms accounted for 80% of life sciences consulting M&A in the past year
  • Valuation trends – Median private market EV/EBITDA at 13.3x, outpacing public market multiples
  • Strong Industry drivers – Demand for AI, regulatory expertise, and real-world evidence (RWE) solutions is fueling M&A
  • Key case studies – Deep dives into leading transactions, including Navitas, Propharma, PLG, and PharmaLex

Submit the form to download >> 

Some of the content of this report is lightly redacted. Contact an Equiteq team member mentioned in the report for the full version.